Indivior Past Earnings Performance
Past criteria checks 0/6
Indivior's earnings have been declining at an average annual rate of -16.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 11.5% per year.
Key information
-16.1%
Earnings growth rate
-16.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 11.5% |
| Return on equity | n/a |
| Net Margin | -0.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indivior makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,182 | -3 | 572 | 105 |
| 30 Jun 24 | 1,147 | -141 | 750 | 101 |
| 31 Mar 24 | 1,124 | 5 | 571 | 107 |
| 31 Dec 23 | 1,093 | 2 | 543 | 106 |
| 30 Sep 23 | 1,042 | -235 | 526 | 106 |
| 30 Jun 23 | 1,002 | -59 | 488 | 108 |
| 31 Mar 23 | 947 | -50 | 469 | 91 |
| 31 Dec 22 | 901 | -53 | 461 | 72 |
| 30 Sep 22 | 882 | 166 | 460 | 62 |
| 30 Jun 22 | 838 | 152 | 460 | 53 |
| 31 Mar 22 | 818 | 166 | 446 | 51 |
| 31 Dec 21 | 791 | 205 | 425 | 52 |
| 30 Sep 21 | 753 | 156 | 402 | 47 |
| 30 Jun 21 | 725 | 139 | 384 | 43 |
| 31 Mar 21 | 674 | 95 | 391 | 39 |
| 31 Dec 20 | 647 | -148 | 427 | 40 |
| 30 Sep 20 | 595 | -190 | 428 | 43 |
| 30 Jun 20 | 634 | -152 | 439 | 47 |
| 31 Mar 20 | 700 | -95 | 427 | 51 |
| 31 Dec 19 | 785 | 134 | 390 | 53 |
| 30 Sep 19 | 889 | 213 | 386 | 53 |
| 30 Jun 19 | 935 | 254 | 404 | 58 |
| 31 Mar 19 | 988 | 248 | 449 | 63 |
| 31 Dec 18 | 1,005 | 275 | 478 | 67 |
| 30 Sep 18 | 1,033 | 106 | 722 | 72 |
| 30 Jun 18 | 1,064 | 67 | 760 | 79 |
| 31 Mar 18 | 1,083 | 71 | 730 | 80 |
| 31 Dec 17 | 1,093 | 58 | 707 | 89 |
| 30 Sep 17 | 1,087 | 281 | 482 | 99 |
| 30 Jun 17 | 1,080 | 81 | 434 | 104 |
| 31 Mar 17 | 1,065 | 65 | 444 | 113 |
| 31 Dec 16 | 1,058 | 35 | 456 | 119 |
| 30 Sep 16 | 1,047 | -6 | 443 | 128 |
| 30 Jun 16 | 1,028 | 191 | 440 | 137 |
| 31 Mar 16 | 1,021 | 201 | 423 | 143 |
| 31 Dec 15 | 1,014 | 228 | 408 | 132 |
| 30 Sep 15 | 1,037 | 268 | 388 | 143 |
| 30 Jun 15 | 1,058 | 314 | 368 | 131 |
| 31 Mar 15 | 1,085 | 361 | 332 | 119 |
| 31 Dec 14 | 1,115 | 403 | 343 | 115 |
| 30 Sep 14 | 1,147 | 443 | 325 | 99 |
| 31 Dec 13 | 1,216 | 489 | 341 | 76 |
Quality Earnings: 2IVB is currently unprofitable.
Growing Profit Margin: 2IVB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2IVB is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare 2IVB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2IVB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 2IVB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.